Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
|Articles|January 1, 1998
Supplements and Featured Publications
- A Managed Care Appraisal of Atypical Agents in the Treatment of Psychoses
- Volume 4
- Issue 1 Suppl
Bibliography
Advertisement
Articles in this issue
almost 29 years ago
Common Treatment Goals: Switching Antipsychoticsalmost 29 years ago
Antipsychotics : Present and Futurealmost 29 years ago
Atypical Antipsychotics in the Managed Care Eraalmost 29 years ago
CME Quizalmost 29 years ago
Selected Abstractsalmost 29 years ago
Participating Facultyalmost 29 years ago
Introduction - The Routine Use of Atypical Antipsychoticsalmost 29 years ago
Atypical Antipsychotics and Formulary Decisionsalmost 29 years ago
Chronic Ambulatory Outpatients and Four-Vector ManagementAdvertisement
Related to this article
Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.
Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.
Leukemia survivors given high-risk ALL therapy had hip bone density about 90% of matched controls, without the partial normalization seen in other groups.
A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
Sacral neuromodulation is still considered the gold standard for refractory overactive bladder, with tibial nerve stimulation a less invasive option.
FDA approved tucatinib maintenance for HER2-positive metastatic breast cancer following induction therapy based on the 654-patient HER2CLIMB-05 trial.
The Omaha-based practice will hand its inbound faxes and document management to artificial intelligence (AI) agents, with outside records retrieval to follow.
Advertisement
Advertisement
Trending on AJMC
1
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
2
5 Things to Know if Retatrutide Is Classified as a Biologic
3
Sacral Neuromodulation Still Seen as OAB Gold Standard in Review
4
FDA Approves Tucatinib Maintenance for HER2+ Metastatic Breast Cancer
5